Vyvanse
(lisdexamfetamine dimesylate) Takeda

Composition:
• Available in capsules with each contains 20 mg, 30 mg and 50 mg of lisdexamfetamine dimesylate for oral administration

Indication:
• For the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.